| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| BioAge Labs, Inc. | Chief Financial Officer | Common Stock | 29,491 | $129,170 | $4.38 | 01 Feb 2026 | Direct |
| Coya Therapeutics, Inc. | Director | Common Stock, par value $0.0001 per share | 27,557 | $30,037 | $1.09 | 18 Aug 2025 | Direct |
| BioAge Labs, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 110,000 | 17 Feb 2026 | Direct | ||
| NeuBase Therapeutics, Inc. | Director | Stock option (right to buy) | 37,600 | 09 Sep 2022 | Direct | ||
| Gain Therapeutics, Inc. | Director | Stock Option (right to buy) | 15,000 | 24 Jun 2025 | Direct | ||
| Coya Therapeutics, Inc. | Director | Stock Option (right to buy) | 10,000 | 02 Jan 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| BIOA | BioAge Labs, Inc. | 17 Feb 2026 | 1 | $0 | 4 | Chief Financial Officer | 19 Feb 2026, 16:38 |
| BIOA | BioAge Labs, Inc. | 01 Feb 2026 | 2 | +$15,510 | 4 | Chief Financial Officer | 03 Feb 2026, 16:23 |
| BIOA | BioAge Labs, Inc. | 16 Jan 2026 | 2 | +$15,514 | 4 | Chief Financial Officer | 21 Jan 2026, 16:20 |
| BIOA | BioAge Labs, Inc. | 13 Jan 2026 | 6 | -$305,298 | 4 | Chief Financial Officer | 15 Jan 2026, 16:22 |
| COYA | Coya Therapeutics, Inc. | 02 Jan 2026 | 1 | $0 | 4 | Director | 06 Jan 2026, 19:27 |
| COYA | Coya Therapeutics, Inc. | 18 Aug 2025 | 2 | +$19,137 | 4 | Director | 19 Aug 2025, 16:01 |
| GANX | Gain Therapeutics, Inc. | 24 Jun 2025 | 1 | $0 | 4 | Director | 25 Jun 2025, 17:30 |
| COYA | Coya Therapeutics, Inc. | 25 Feb 2025 | 1 | $0 | 4 | Director | 25 Feb 2025, 21:30 |
| BIOA | BioAge Labs, Inc. | 18 Feb 2025 | 1 | $0 | 4 | Chief Financial Officer | 20 Feb 2025, 16:19 |
| COYA | Coya Therapeutics, Inc. | 01 Jan 2025 | 1 | $0 | 4 | Director | 03 Jan 2025, 21:31 |
| BIOA | BioAge Labs, Inc. | 25 Sep 2024 | 0 | $0 | 3 | Chief Financial Officer | 25 Sep 2024, 16:45 |
| GANX | Gain Therapeutics, Inc. | 24 Jun 2024 | 1 | $0 | 4 | Director | 26 Jun 2024, 21:30 |
| COYA | Coya Therapeutics, Inc. | 01 Jan 2024 | 1 | $0 | 4 | Director | 19 Jan 2024, 18:30 |
| GANX | Gain Therapeutics, Inc. | 23 Jun 2023 | 1 | $0 | 4 | Director | 26 Jun 2023, 16:38 |
| COYA | Coya Therapeutics, Inc. | 03 Jan 2023 | 2 | $0 | 4 | Director | 04 Jan 2023, 07:30 |
| COYA | Coya Therapeutics, Inc. | 28 Dec 2022 | 0 | $0 | 3 | Director | 28 Dec 2022, 19:38 |
| GANX | Gain Therapeutics, Inc. | 20 Sep 2022 | 1 | $0 | 4 | Director | 22 Sep 2022, 16:10 |
| /report/000110465922099286-goldstein-dov-a-md-2022-09-09 | NeuBase Therapeutics, Inc. | 09 Sep 2022 | 1 | $0 | 4 | Director | 12 Sep 2022, 17:00 |
| /report/000110465921116925-goldstein-dov-a-md-2021-08-19 | NeuBase Therapeutics, Inc. | 19 Aug 2021 | 1 | $0 | 4 | Director | 17 Sep 2021, 16:17 |
| /report/000110465921083253-goldstein-dov-a-md-2021-06-18 | NeuBase Therapeutics, Inc. | 18 Jun 2021 | 1 | +$38,000 | 4 | Director | 21 Jun 2021, 11:03 |